Aarhus University Seal / Aarhus Universitets segl

Peter Vedsted

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Dokumenter

  • 530.full

    Forlagets udgivne version, 735 KB, PDF-dokument

DOI

  • Henrik Møller
  • Victoria H Coupland
  • ,
  • Daniela Tataru, National Cancer Registration and Analysis Service, Public Health England, Skipton House, 80 London Road, London SE1 6LH, UK.
  • ,
  • Michael D Peake, Department of Respiratory Medicine, University of Leicester, Glenfield Hospital, Leicester, UK.
  • ,
  • Anders Mellemgaard, Department of Oncology, Herlev Hospital - University Copenhagen, Denmark.
  • ,
  • Thomas Round, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • ,
  • David R Baldwin, Division of Respiratory Medicine, University of Nottingham, Nottingham City Hospital, Nottingham, UK.
  • ,
  • Matthew E J Callister, Department of Respiratory Medicine, St James's University Hospital, Leeds, UK.
  • ,
  • Erik Jakobsen, Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark
  • ,
  • Peter Vedsted
  • Richard Sullivan, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • ,
  • James Spicer, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

INTRODUCTION: Lung cancer outcomes in England are inferior to comparable countries. Patient or disease characteristics, healthcare-seeking behaviour, diagnostic pathways, and oncology service provision may contribute. We aimed to quantify associations between geographic variations in treatment and survival of patients in England.

METHODS: We retrieved detailed cancer registration data to analyse the variation in survival of 176,225 lung cancer patients, diagnosed 2010-2014. We used Kaplan-Meier analysis and Cox proportional hazards regression to investigate survival in the two-year period following diagnosis.

RESULTS: Survival improved over the period studied. The use of active treatment varied between geographical areas, with inter-quintile ranges of 9%-17% for surgical resection, 4%-13% for radical radiotherapy, and 22%-35% for chemotherapy. At 2 years, there were 188 potentially avoidable deaths annually for surgical resection, and 373 for radical radiotherapy, if all treated proportions were the same as in the highest quintiles. At the 6 month time-point, 318 deaths per year could be postponed if chemotherapy use for all patients was as in the highest quintile. The results were robust to statistical adjustments for age, sex, socio-economic status, performance status and co-morbidity.

CONCLUSION: The extent of use of different treatment modalities varies between geographical areas in England. These variations are not attributable to measurable patient and tumour characteristics, and more likely reflect differences in clinical management between local multi-disciplinary teams. The data suggest improvement over time, but there is potential for further survival gains if the use of active treatments in all areas could be increased towards the highest current regional rates.

OriginalsprogEngelsk
TidsskriftThorax
Sider (fra-til)530–537
ISSN0040-6376
DOI
StatusUdgivet - jun. 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 123440634